- Home
- NVNI vs PULM Comparison
NVNI vs PULM Comparison
Compare NVNI & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNI
- PULM
- Stock Information
- Founded
- NVNI 2019
- PULM 2003
- Country
- NVNI Brazil
- PULM United States
- Employees
- NVNI N/A
- PULM N/A
- Industry
- NVNI
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- NVNI
- PULM Health Care
- Exchange
- NVNI Nasdaq
- PULM Nasdaq
- Market Cap
- NVNI 31.5M
- PULM 33.2M
- IPO Year
- NVNI N/A
- PULM N/A
- Fundamental
- Price
- NVNI $0.34
- PULM $6.15
- Analyst Decision
- NVNI
- PULM
- Analyst Count
- NVNI 0
- PULM 0
- Target Price
- NVNI N/A
- PULM N/A
- AVG Volume (30 Days)
- NVNI 1.2M
- PULM 57.4K
- Earning Date
- NVNI 08-07-2025
- PULM 08-12-2025
- Dividend Yield
- NVNI N/A
- PULM N/A
- EPS Growth
- NVNI N/A
- PULM N/A
- EPS
- NVNI N/A
- PULM N/A
- Revenue
- NVNI $31,250,627.00
- PULM $1,921,000.00
- Revenue This Year
- NVNI $12.05
- PULM N/A
- Revenue Next Year
- NVNI $15.02
- PULM $134.88
- P/E Ratio
- NVNI N/A
- PULM N/A
- Revenue Growth
- NVNI 1491.58
- PULM N/A
- 52 Week Low
- NVNI $0.14
- PULM $1.78
- 52 Week High
- NVNI $12.19
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- NVNI 52.07
- PULM 37.18
- Support Level
- NVNI $0.34
- PULM $6.28
- Resistance Level
- NVNI $0.38
- PULM $6.83
- Average True Range (ATR)
- NVNI 0.03
- PULM 0.35
- MACD
- NVNI 0.01
- PULM -0.07
- Stochastic Oscillator
- NVNI 67.35
- PULM 0.00
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).